Drugs /

sotorasib

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
sotorasib
NCI Definition [1]:
An orally available agent that targets the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets the KRAS p.G12C mutant, at either the DNA, RNA or protein level, and prevents, through an as of yet not elucidated manner, expression of and/or tumor cell signaling through the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. The KRAS p.G12C mutation is seen in some tumor cell types and plays a key role in tumor cell proliferation.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for sotorasib

Sotorasib has been investigated in 5 clinical trials, of which 5 are open and 0 are closed. Of the trials investigating sotorasib, 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open).

KRAS G12C, PD-L1 No Expression (TPS < 1%), and STK11 Loss are the most frequent biomarker inclusion criteria for sotorasib clinical trials.

Non-small cell lung carcinoma, malignant solid tumor, and adenosquamous lung carcinoma are the most common diseases being investigated in sotorasib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Sotorasib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating sotorasib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
amg 510, amg-510, amg510
Drug Target(s) [2]:
KRAS
NCIT ID [1]:
C154287

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.